Radar · Oncology in Canada
Best Oncology Companies in Canada
The 183 best Oncology companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Virogin Biotech.
By Riya SenguptaFinancials
183companies tracked
$2.9Bdisclosed funding
0unicorns
97have raised
Canada's oncology sector gets a proper ranking here: 183 companies tracked, sorted by disclosed equity funding and recent momentum, so you can cut straight to who's actually capitalized. Total disclosed funding across the cohort sits at $2.9B, and the global market backdrop justifies the attention: oncology is forecast to reach roughly $668B by 2034, compounding at 11.5% annually on the back of rising cancer incidence and precision medicine expansion. Cost-containment policies are the structural headwind every Canadian filer has to price in, but the capital keeps moving.
So who's pulling the most weight? ABK Biomedical leads the directory at $79M in disclosed funding, with Helix BioPharma at $36M and Exact Imaging at $30M not far behind. That's a realistic funding range for a sector where clinical validation is expensive and timelines are long. I'd note that BDC, adMare BioInnovations, and Lumira Ventures are the most active backers in this cohort, which tells you something about the institutional conviction here. Hot themes right now include cancer biomarkers and angiogenesis inhibitors, and AI's expanding role in oncology genetics is reshaping how Canadian companies position their pipelines. No unicorns yet. But the foundations are being laid.
Sources & further reading
- Oncology R&D: emerging therapies and new challenges
- Oncology Market Size to Surpass USD 903.81 Billion by 2034
FLIAR INTELLIGENCE · ONCOLOGY × CANADA
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
226kcombined LinkedIn audience
44%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Virogin Biotech Developed of drugs for the treatment of cancer | $281M | 56 mo ago | 56 | 2015 | William Jia Co-Founder | — | 103 patents Engineered oncolytic viruses for targeted cancer immunotherapy and viral vector platforms | — |
| 2 | Fusion Pharmaceuticals Developer of targeted alpha therapeutics for the treatment of cancers | $171M | 77 mo ago | 106 | 2014 | — | — | 294 patents Patents concentrated in health & consumer products | — |
| 3 | Repare Therapeutics Developer of targeted therapies to address the genetic alterations associated with selected tumors | $166M | 72 mo ago | 180 | 2016 | Daniel Durocher Co-Founder | 6 signals ▲100% Earnings · M&A · Contracts | 161 patents Small‑molecule kinase inhibitors for cancer therapy, focusing on PLK4, ATR, MYT1 targets. | — |
| 4 | Zymeworks Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 29 mo ago | 277 277 → 271 (-2%) | 2003 | — | 39 signals ▲34% Leadership · Board · Buyback | 1,015 patents Design and production of bispecific/trispecific recombinant antibody therapeutics targeting cancer antigens. | — |
| 5 | Abdera Therapeutics Provider of therapeutics for cancer treatment. | $142M | 38 mo ago | 20 | 2020 | Adam Judge Co-Founder | — | 9 patents DLL3-targeted radioimmunoconjugates and chelator technologies for cancer radionuclide therapy | — |
| 6 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 77 mo ago | — | 2012 | Xiaonan Wang Co-Founder & CTO | — | — | — |
| 7 | Abcellera Biologics AI-enabled platform for antibodies discovery | $115M | 60 mo ago | 560 | 2012 | — | 6 signals ▲50% Earnings · Lawsuit | 50 patents Therapeutic antibody discovery using transgenic rodent platforms and computational affinity modeling | 1 partnership |
| 8 | Trillium Therapeutics Developer of therapeutics for the treatment of cancer | $102M | 69 mo ago | 33 | 1996 | — | — | 180 patents Immune checkpoint therapies targeting CD47 with antibody and combination strategies | — |
| 9 | Notch Therapeutics Developer of stem-cell derived immune cell therapies | $100M | 25 mo ago | 90 | 2018 | Shreya Shukla Founder | — | 18 patents Engineered T‑cell immunotherapies from stem cells and AI‑driven cellular outcome prediction | — |
| 10 | Alpha-9 Theranostics Developer of molecules for solid and hematologic malignancies | $84M | 42 mo ago | 24 | 2019 | Ian McBeath CEO | — | 6 patents Radiopharmaceuticals targeting PSMA and CXCR4 for cancer imaging and therapy | — |
| 11 | Angle Developer of cancer cell capture and analysis equipment | $81M | 47 mo ago | 176 | 1994 | — | 3 signals Leadership · Earnings | — | — |
| 12 | ABK Biomedical Developer of imageable embolic medical devices targeting benign and malignant hypervascular tumors 48Funding top 24%Moat top 32%Growth top 35%Patents top 36% All 10 signals ▾Fundingtop 24% Moattop 32% Growthtop 35% Patentstop 36% Talenttop 38% Innovationtop 39% Techbottom 48% Newsbottom 42% Globalbottom 42% Marketbottom 20% Funding: Raised $79.3M across 7 rounds · 7 rounds over 14 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 43 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $79M | 8 mo ago | 1 | 2012 | Sharon Kehoe Co-Founder | — | 43 patents Medical drug delivery devices and radiopaque microparticle formulations for imaging and therapy | — |
| 13 | ProNAi Therapeutics Developer of DNA-based gene therapies for cancer and other genetic diseases | $77M | 145 mo ago | — | 2004 | Nick Glover President and CEO | — | — | — |
| 14 | Sierra Oncology Developer of targeted therapies to treat cancer | $75M | 145 mo ago | 109 | 2003 | — | — | — | — |
| 15 | Bellus Health Developer of drugs for treating rare diseases | $71M | 88 mo ago | 13 | 1993 | — | — | 107 patents Patents concentrated in health & consumer products | — |
| 16 | Aquinox Pharma Small molecule targeting PI3K pathway. | $71M | 158 mo ago | — | 2004 | — | — | — | — |
| 17 | OncoQuest Developing tumor antigen-specific monoclonal IgE antibodies for combinatorial immunotherapy | $69M | 75 mo ago | 9 | 2015 | — | — | 21 patents Targeted monoclonal antibody cancer therapies combined with immune adjuvants and delivery enhancers | — |
| 18 | StageZero Life Sciences Developer of liquid biopsy test for the detection of cancer and multiple diseases | $59M | 46 mo ago | 40 | 1997 | James Tripp CEO | — | — | — |
| 19 | Aptose Biosciences Targeted small molecules for the treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes. | $52M | 28 mo ago | 31 | 1986 | — | 14 signals ▲40% Contracts · Announcements · Funding | 69 patents Patents concentrated in health & consumer products | — |
| 20 | Oncolytics Biotech Develops oncolytic viruses for use as cancer therapeutics 48Patents top 29%Product top 30%Funding top 31%News top 33% All 11 signals ▾Patentstop 29% Producttop 30% Fundingtop 31% Newstop 33% Innovationtop 41% Moattop 41% Growthtop 47% Techtop 47% Talentbottom 49% Marketbottom 38% Globalbottom 37% Patents: 450 patents matched (strict assignee match) · 6 filings since 2022 vs 40 in 2017-21 Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 48/100 | $48M | 14 mo ago | 29 | 1998 | Matt Coffey President and Chief Executive Officer | 16 signals ▼43% Earnings · Acquisition · Regulatory | 450 patents Oncolytic virotherapy and viral formulation for cancer immunotherapy | — |
| 21 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 21 mo ago | 11 | 2020 | — | — | 38 patents Multispecific antibody therapeutics targeting TNF receptors and cytokine pathways | — |
| 22 | KisoJi Developer of multi-specific antibodies for cancer treatment | $41M | 20 mo ago | — | 2009 | David Young Co-Founder & CEO | — | — | — |
| 23 | 3T Biosciences Developer of T-cell-based cancer immunotherapies to fight cancer | $40M | 45 mo ago | 33 | 2017 | Leah Sibener Co-Founder | 3 signals Leadership | 27 patents High‑density EGFR/ErbB2‑targeted antibodies for cancer diagnostics and therapy | — |
| 24 | Helix BioPharma Developer of therapies for the treatment and prevention of cancer 35Product top 14%Moat top 28%Funding top 34%Patents top 38% All 11 signals ▾Producttop 14% Moattop 28% Fundingtop 34% Patentstop 38% Innovationtop 44% Techtop 47% Talentbottom 49% Growthbottom 47% Newsbottom 43% Globalbottom 43% Marketbottom 23% Product: 5 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 110 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $36M | 9 mo ago | 7 | 1995 | Jacek Antas Ceo & Chairman Of The Executive Board | 3 signals ▼83% Regulatory · Announcements · Earnings | 110 patents Engineered immune‑cell and antibody‑enzyme therapeutics for tumor microenvironment modulation | — |
| 25 | Ability Developer of modulating biotherapeutics to address cancer and autoimmune diseases | $30M | 24 mo ago | — | 2023 | Jean Buerckert Co-Founder & CTO | — | — | 1 internship |
| 26 | Exact Imaging Developer of micro-ultrasound based imaging device 45Funding top 28%Moat top 32%Growth top 35%Patents top 46% All 9 signals ▾Fundingtop 28% Moattop 32% Growthtop 35% Patentstop 46% Talentbottom 49% Innovationbottom 47% Techbottom 44% Globalbottom 42% Marketbottom 39% Funding: Raised $29.9M across 5 rounds · 5 rounds over 13 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 45 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 4 mo ago | 32 | 2013 | Randy Aucoin President & CEO | — | 45 patents High‑resolution ultrasound imaging and needle‑guidance systems for interventional diagnostics | — |
| 27 | Qu Biologics Developing Site Specific Immunomodulators that aim to reboot the body's immune system to treat cancer and… | $30M | 51 mo ago | 22 | 2007 | — | — | 80 patents Innate immune modulation for cell therapies, anti‑inflammatory and antimicrobial biologics | — |
| 28 | Sunshine Biopharma Developer of antiviral and anticancer drugs | $28M | 37 mo ago | 46 | 2009 | — | — | 2 patents Patents concentrated in health & consumer products | — |
| 29 | Zenith Epigenetics Developer of small molecule BET inhibitors for cancer and autoimmune disorders 21Moat top 28%Patents top 33%Innovation top 42%Funding top 50% All 9 signals ▾Moattop 28% Patentstop 33% Innovationtop 42% Fundingtop 50% Productbottom 47% Globalbottom 37% Marketbottom 28% Techbottom 28% Newsbottom 27% Moat: Editorial + unicorn rating 4/10 · IP moat: 187 patents Patents: 187 patents matched (strict assignee match) · 23 filings since 2022 vs 115 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $17M | 13 mo ago | 16 | 2013 | — | — | 187 patents Patents concentrated in health & consumer products | — |
| 30 | Sound Blade Medical Developer of a compact ultrasound therapy platform for non-invasive treatment of various pathologies | $16M | 16 mo ago | — | 2023 | Matthew Mallay Co-Founder | — | — | — |
| 31 | Alethia BioTherapeutics Developing monoclonal antibody-based therapeutics for cancer-associated diseases. | $14M | 20 mo ago | 12 | 2002 | — | — | 205 patents Engineered peptide immunotherapies enhancing tumor-infiltrating lymphocyte infiltration. | — |
| 32 | Profound Medical Developer of image guided prostate ablation system for cancer treatment 80Patents top 25%Funding top 31%Innovation top 33%Tech top 34% All 12 signals ▾Patentstop 25% Fundingtop 31% Innovationtop 33% Techtop 34% Moattop 35% Growthtop 36% Newstop 39% Markettop 40% Fin. healthtop 41% Globaltop 44% AItop 45% Partnerstop 45% Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $13M | 6 mo ago | 131 | 2008 | — | 19 signals ▼24% Earnings · Announcements · Funding | 171 patents Patents concentrated in health & consumer products | — |
| 33 | Reverb Therapeutics Developer of treatments for cancer and other diseases | $12M | 15 mo ago | — | 2022 | Surjit Dixit Co-Founder | — | — | — |
| 34 | Syantra Health Developer of a blood test device to detect breast cancer 53Talent top 23%AI top 30%Growth top 35%Funding top 39% All 8 signals ▾Talenttop 23% AItop 30% Growthtop 35% Fundingtop 39% Moattop 48% Techbottom 40% Globalbottom 36% Marketbottom 29% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 53/100 | $10M | 3 mo ago | 15 | 2013 | Kenneth Fuh Co-Founder | — | — | — |
| 35 | Providence Therapeutics Developer of mRNA-based therapeutics for cancer and covid-19 treatment 55Patents top 24%Moat top 32%Innovation top 35%Growth top 35% All 11 signals ▾Patentstop 24% Moattop 32% Innovationtop 35% Growthtop 35% Talenttop 38% Fundingtop 43% Marketbottom 49% Newsbottom 45% Globalbottom 43% Partnersbottom 35% Techbottom 29% Patents: 54 patents matched (strict assignee match) · 54 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 54 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $9M | 13 mo ago | 68 | 2015 | Eric Marcusson Co-Founder | — | 54 patents Lipid nanoparticle platforms for nucleic acid vaccine delivery and therapeutic formulations | — |
| 36 | Rakovina Therapeutics Developer of precision medicine to kill cancer cells 27Funding top 37%Patents top 40%Tech top 46%Growth top 47% All 9 signals ▾Fundingtop 37% Patentstop 40% Techtop 46% Growthtop 47% Newstop 48% Moatbottom 49% Innovationbottom 48% Globalbottom 35% Marketbottom 18% Funding: Raised $7.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 9 patents matched (strict assignee match) · 8 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $8M | 13 mo ago | 6 | 2020 | — | 6 signals ▼33% Board · Earnings | 9 patents Dual PARP‑HDAC inhibitor therapeutics for DNA‑repair and epigenetic cancer treatment | — |
| 37 | Pattern Pharma Developer of immunotherapies to treat cancers and infectious diseases | $7M | 14 mo ago | 5 | 2018 | — | — | — | — |
| 38 | Telo Genomics Developer of non-invasive prognostic and diagnostic applications that improve disease treatment 37Moat top 31%News top 38%Talent top 39%Partners top 40% All 11 signals ▾Moattop 31% Newstop 38% Talenttop 39% Partnerstop 40% Patentstop 43% Fundingtop 44% AItop 45% Growthtop 48% Innovationbottom 48% Globalbottom 33% Marketbottom 24% Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 3 mo ago | 6 | 2011 | Sherif Louis CEO | 9 signals ▼25% Leadership · Funding · Contracts | 9 patents Diagnostic assays for smoldering multiple myeloma using nucleic‑acid biomarkers | — |
| 39 | Biomark Diagnostics Provider of metabolomics-based diagnostics for cancer | $5M | 14 mo ago | 6 | 2007 | — | — | — | — |
| 40 | Avitia Provider of AI-powered diagnostics platform for molecular cancer testing solutions | $5M | 15 mo ago | — | 2025 | James Lumsdaine Chief Executive Officer | — | — | — |
| 41 | Mesentech Developer of therapies for treating bone disorders | $4M | 17 mo ago | 13 | 2016 | Ian McBeath Founder & Co-CEO | — | — | — |
| 42 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 1 mo ago | — | 2022 | John Bell Co-Founder | — | — | — |
| 43 | PreveCeutical Developer of peptide based therapuetics for cancer treatment | $2M | 12 mo ago | 7 | 2015 | Mak Jawadekar Co-Founder | 9 signals Leadership · Regulatory · Funding | — | — |
| 44 | Onco-Innovations Developer of therapeutics for cancer treatment 35Funding top 39%Tech top 41%Growth top 45%Talent bottom 49% All 6 signals ▾Fundingtop 39% Techtop 41% Growthtop 45% Talentbottom 49% Marketbottom 31% Globalbottom 25% Funding: Raised $1.9M across 3 rounds · 3 rounds over 1 yrs (3.0/yr) Tech: 26 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 35/100 | $2M | 4 mo ago | — | 2024 | Thomas O Shaughnessy CEO | — | — | 2 partnerships |
| 45 | Proteocyte Provider of diagnostic test to predict risk of developing cancers | $2M | 13 mo ago | 5 | 2011 | — | — | — | 2 launchs |
| 46 | Starpax Biopharma Developer of therapeutics for the treatment of cancer | $782K | 16 mo ago | — | 2017 | Michael Gareau Founder & CEO | — | 20 patents Magnetic navigation and control of therapeutic agents for targeted drug delivery | — |
| 47 | Novation Pharmaceuticals Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform | $626K | 15 mo ago | — | 1999 | Dominique Cheneval President and Co-Founder | — | 21 patents Novel benzopyran therapeutics and mRNA‑stability screening assays for drug discovery | — |
| 48 | Soricimed Biopharma Specialty company developing peptide-based cancer therapeutics | $609K | 14 mo ago | 8 | 2005 | — | — | 47 patents Patents concentrated in health & consumer products | — |
| 49 | StokedBio Developer of therapeutics based on AI technology 45Talent top 28%AI top 45%Funding top 46%Market bottom 37% All 5 signals ▾Talenttop 28% AItop 45% Fundingtop 46% Marketbottom 37% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 45/100 | $366K | 1 mo ago | — | 2024 | Chris Sinclair Co-Founder | — | — | — |
| 50 | IMBiotechnologies Manufacturer of embolotherapy products for the treatment of cancer | $129K | 13 mo ago | 2 | 2008 | Irwin Griffith Co-Founder | — | 19 patents Ultrasound‑activated embolic compositions for targeted vascular occlusion | — |
Top 12 Oncology companies in Canada
#1
Series D · Markham, Ontario · founded 2013 · 32 employees$29.9Mraised▾
Series D · Markham, Ontario · founded 2013 · 32 employees
Exact Imaging has developed a micro-ultrasound based imaging device. The ExactVu system operates at 29MHz waves for higher resolution and is used for imaging prostate cancer and biopsies. The product has an integrated disposable needle biopsy apparatus for visualization and targeting of suspicious small regions. in real-time
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Growth
top 35%Patents
top 46%Talent
bottom 49%Innovation
bottom 47%Funding: Raised $29.9M across 5 rounds · 5 rounds over 13 yrs (0.4/yr) · Last round Series D (Feb 2026)
Moat: Editorial + unicorn rating 7/10 · IP moat: 45 patents · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Feb 2026Series D$10M
- Aug 2019Series C$244.4K
- Feb 2019Series C$7.6M
- Jan 2017Series C$16.1M
Founders & team
Investors
iGan Partners, Veddis App, MaRS IAF, Lumira Ventures, Vesalius Biocapital Partners, PMV
Tech stack
Adobe Experience Platform LaunchApache Http ServerBootstrapCallrailCloudflareCloudflare Bot Management
#2
Series D · Halifax, Nova Scotia · founded 2012 · 1 employees$79.3Mraised▾
Series D · Halifax, Nova Scotia · founded 2012 · 1 employees
Developer of imageable embolic medical devices targeting benign and malignant hypervascular tumors. It offers Eye90 microspheres which are Y‑90 radioembolization microspheres designed for liver tumor therapy, combining tumor treatment with advanced CT imaging visibility for precise dosimetry and visualization. It also offer Easi-Vue embolic microsphere which is an imageable bland embolization product allowing direct visualization at the target site.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 24%Moat
top 32%Growth
top 35%Patents
top 36%Talent
top 38%Innovation
top 39%Funding: Raised $79.3M across 7 rounds · 7 rounds over 14 yrs (0.5/yr) · Last round Series D (Oct 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 43 patents · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 6k LinkedIn followers — 2.5% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. University of Missouri Research Reactor (MURR)) announced in 12 mo
Funding rounds
- Oct 2025Series D$35M
- Apr 2025Series C$26.1M
- Dec 2022Series C$30M
- Sep 2022Series B$18.1M
Founders & team
Investors
Invest Nova Scotia, F-Prime Capital, Varian Medical Systems, Sante, Eight Roads Ventures, Atlantic Canada Opportunities Agency
Tech stack
CloudflareCloudflare Bot ManagementDiviGoogle AnalyticsGoogle Font ApiJquery
#3
Series A · Calgary, Alberta · founded 2013 · 15 employees$10.4Mraised▾
Series A · Calgary, Alberta · founded 2013 · 15 employees
Developer of a blood test device to detect breast cancer. The company offers the Syantra DX device for blood-based cancer detection test that utilizes a combination of biomarkers and artificial intelligence-generated algorithms for molecular diagnostics. It captures and decodes changes in how the body is functioning. It enables earlier detection and effective treatment of cancer.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Talent
top 23%AI
top 30%Growth
top 35%Funding
top 39%Moat
top 48%Tech
bottom 40%Talent: 6 named leaders on record · 6 C-suite/founder profiles curated
AI: Classified as an AI company · Product described with: artificial intelligence
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Mar 2026Grant (prize money)$2.4M
- Sep 2024Series A$3.6M
- Jan 2022Series A$6.8M
- Jun 2021Seed—
Founders & team
Investors
The51, Canaccord Genuity Group, Plug and Play Tech Center, Accelerate Fund, Department of War, Innovate Calgary
Tech stack
CloudflareGoogle AnalyticsHstsHttp/3JqueryMicrosoft 365
#4
Public · Toronto, Ontario · founded 2008 · 131 employees$12.9Mraised▾
Public · Toronto, Ontario · founded 2008 · 131 employees
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Patents
top 25%Funding
top 31%Innovation
top 33%Tech
top 34%Moat
top 35%Growth
top 36%Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 · Latest publication 2026
Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) · Last round Post IPO (Dec 2025)
Innovation: 171 patents (top 16% of patent-holders) · 60 filings since 2022 vs 85 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 18k LinkedIn followers — 7.9% of this cohort's audience
Funding rounds
- Dec 2025Post IPO$6.5M
- Jan 2024Post IPO—
- Jul 2020Post IPO$46M
- Mar 2018Post IPO$34.5M
Investors
BDC, Genesys Capital, FedDev Ontario, Knight Therapeutics, Stifel, Cormark Securities
Tech stack
Amazon CloudfrontAmazon Web ServicesApache Http ServerBootstrapChart.JsCloudflare
#5
Public · Aurora, Ontario · founded 1995 · 7 employees$36.2Mraised▾
Public · Aurora, Ontario · founded 1995 · 7 employees
Developer of therapies for the treatment and prevention of cancer. The pipeline candidates include topical interferon - alpha2b, and LDOS47 for the treatment of small-cell lung cancer and pancreatic cancer. The company also has a patented technology platform DOS47 focused on achieving better debilitation of cancer cells.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Product
top 14%Moat
top 28%Funding
top 34%Patents
top 38%Innovation
top 44%Tech
top 47%Product: 5 distinct product lines · Company stage: Public
Moat: Editorial + unicorn rating 5/10 · IP moat: 110 patents
Funding: Raised $36.2M across 21 rounds · 21 rounds over 9 yrs (2.3/yr) · Last round Post IPO (Aug 2025)
Funding rounds
- Aug 2025Post IPO$1.7M
- Jan 2025Post IPO$2.1M
- Mar 2024Post IPO$1.4M
- Nov 2022Post IPO$3.4M
Founders & team
Investors
Jerzy Wilczewski
Tech stack
Apache Http ServerAutoptimizeBootstrapCloudflareContact Form 7Core-Js
#6
Public · Toronto, Ontario · founded 2011 · 6 employees$5.5Mraised▾
Public · Toronto, Ontario · founded 2011 · 6 employees
Developer of non-invasive prognostic and diagnostic applications that improve disease treatment. The company has a proprietary technology that uses a quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability. It is developing Telo-MM application to provide e information to medical professionals in the treatment of Multiple Myeloma.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Moat
top 31%News
top 38%Talent
top 39%Partners
top 40%Patents
top 43%Funding
top 44%Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents
News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Talent: 1 named leader on record · 1 C-suite/founder profile curated · 5 leadership moves in 12 mo
Audience (LinkedIn): 845 LinkedIn followers
Funding rounds
- Mar 2026Post IPO—
- Dec 2024Post IPO$1.8M
- May 2023Post IPO$2M
- Jul 2021Post IPO$1.7M
Founders & team
#7
Seed · Ottawa, Ontario · founded 2022$2.4Mraised▾
Seed · Ottawa, Ontario · founded 2022
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Talent
top 28%Funding
top 45%Global
bottom 33%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (May 2026)
Global: Single-market focus (Canada)
Audience (LinkedIn): 682 LinkedIn followers
Funding rounds
- May 2026Seed$365.5K
- Jan 2025Seed$2M
- Dec 2024Grant (prize money)—
Founders & team
Investors
FACIT, GKCC, Government of Canada, Ontario Canada
#8
Public · Calgary, Alberta · founded 1998 · 29 employees$48.1Mraised▾
Public · Calgary, Alberta · founded 1998 · 29 employees
Oncolytics Biotech is a development-stage biotechnology company that develops oncolytic viruses for use as cancer therapeutics. The company's leading product, REOLYSIN, is developed from the reovirus. Oncolytics Biotech claims that the virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. The wholly owned subsidiaries of the Company include Oncolytics Biotech (Barbados) and Oncoltics Biotech (US).
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Patents
top 29%Product
top 30%Funding
top 31%News
top 33%Innovation
top 41%Moat
top 41%Patents: 450 patents matched (strict assignee match) · 6 filings since 2022 vs 40 in 2017-21 · Latest publication 2026
Product: 1 distinct product line · Company stage: Public
Funding: Raised $48.1M across 3 rounds · 3 rounds over 16 yrs (0.2/yr) · Last round Post IPO (Apr 2025)
Audience (LinkedIn): 6k LinkedIn followers — 2.7% of this cohort's audience
Funding rounds
- Apr 2025Post IPO$20M
- Oct 2010Post IPO$24M
- Post IPO$4.1M
Founders & team
Investors
Paradigmcap, RBC Capital Markets, Alumni Capital
Tech stack
AstraCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor
#9
Seed · Calgary, Alberta · founded 2013 · 16 employees$16.6Mraised▾
Seed · Calgary, Alberta · founded 2013 · 16 employees
Zenith Epigenetics is a developer of small molecule BET inhibitors for cancer and autoimmune disorders. The company’s proprietary epigenetic drug discovery platform functions by inhibiting BET bromodomains. Its lead product, ZEN-3694, is a BET inhibitor developed for hematological malignancies and solid tumors including prostate cancer. It can be act as a single therapeutic solution for prostate cancer.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Moat
top 28%Patents
top 33%Innovation
top 42%Funding
top 50%Product
bottom 47%Global
bottom 37%Moat: Editorial + unicorn rating 4/10 · IP moat: 187 patents
Patents: 187 patents matched (strict assignee match) · 23 filings since 2022 vs 115 in 2017-21 · Latest publication 2025
Innovation: 187 patents (top 14% of patent-holders) · 23 filings since 2022 vs 115 in 2017-21 · 2 product lines
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2025Seed$1.5M
- Apr 2025Seed—
- Apr 2025Conventional Debt$320.8K
- Mar 2025Conventional Debt$185.2K
Tech stack
AddthisBootstrapFancyboxFont AwesomeGoogle AnalyticsJquery
#10
Public · Calgary, Alberta · founded 2024$1.9Mraised▾
Public · Calgary, Alberta · founded 2024
Developer of therapeutics for cancer treatment. It offers technology that targets solid tumours that improve patient outcomes and fight against cancer which include colorectal cancer, breast cancer and lung cancer.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 39%Tech
top 41%Growth
top 45%Talent
bottom 49%Market
bottom 31%Global
bottom 25%Funding: Raised $1.9M across 3 rounds · 3 rounds over 1 yrs (3.0/yr) · Last round Post IPO (Jan 2026)
Tech: 26 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 208 LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Nanosoft Polymers) announced in 12 mo
Funding rounds
- Jan 2026Post IPO$880K
- Jul 2025Post IPO$291.5K
- Jan 2025Post IPO$696.8K
Founders & team
Tech stack
Framer SitesGodaddyGoogle Font ApiHstsHttp/3Microsoft 365
#11
Series A · Calgary, Alberta · founded 2015 · 68 employees$8.5Mraised▾
Series A · Calgary, Alberta · founded 2015 · 68 employees
Developer of mRNA-based therapeutics for cancer and covid-19 treatment. The company's mRNA vaccines are customized based on the patient's tumor-specific mutations to induce an immune response. It generates strong T-cell responses that aim to kill cancer cells and destroy tumors. Also, developed PTX-COVID19-B and PTX-COVID19-LT for covid-19 treatment.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Patents
top 24%Moat
top 32%Innovation
top 35%Growth
top 35%Talent
top 38%Funding
top 43%Patents: 54 patents matched (strict assignee match) · 54 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 7/10 · IP moat: 54 patents · 10 curated direct competitors tracked
Innovation: 54 patents (top 46% of patent-holders) · 54 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 7k LinkedIn followers — 3.2% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2025Conventional Debt$711.6K
- May 2025Series A$711.6K
- Mar 2025Series A$209.8K
- Jan 2025Series A$395.4K
Founders & team
Investors
NGen, Gates, JLABS
Tech stack
Animate.CssApache Http ServerBootstrapBunnyGodaddyGoogle Analytics
#12
Seed · Hamilton, Ontario · founded 2024$365.5Kraised▾
Seed · Hamilton, Ontario · founded 2024
Developer of therapeutics based on AI technology. It offers AI-based platform for molecular property prediction and molecular design for drug discovery for antibacterial, antifungal, antiviral, and cancer applications.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Talent
top 28%AI
top 45%Funding
top 46%Market
bottom 37%Global
bottom 29%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
AI: Product described with: ai-based
Funding: Raised $366k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (May 2026)
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. McMaster) announced in 12 mo
Funding rounds
- May 2026Seed$365.5K
Founders & team
Investors
Ontario Canada
Funding & investor landscape
$2.9Btotal disclosed funding
88companies funded
347disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
Randy Aucoin
President & CEO · Exact Imaging
Sharon Kehoe
Co-Founder · ABK Biomedical
Michael Mangano
CEO & President · ABK Biomedical
Kenneth Fuh
Co-Founder · Syantra Health
Bob Shepherd
Co-Founder & COO · Syantra Health
Jacek Antas
Ceo & Chairman Of The Executive Board · Helix BioPharma
Sherif Louis
CEO · Telo Genomics
John Bell
Co-Founder · Esphera SynBio
Brian Lichty
Co-Founder & CEO · Esphera SynBio
Matt Coffey
President and Chief Executive Officer · Oncolytics Biotech
Thomas O Shaughnessy
CEO · Onco-Innovations
Eric Marcusson
Co-Founder · Providence Therapeutics
Prism market signals · Canada · country-scoped Prism corpus, 8,189,618 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Canada
How research on Oncology & Cancer Therapeutics is moving in Canada
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,276 Canada-affiliated papers.
research sentiment over time
201120192026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 55% → 66% across 2011–2026.
top research entities
- Ministry of Education247
- University of Toronto121
- McGill University107
- Princess Margaret Cancer Centre93
- Institute of Cancer Research91
leading researchers
Lautert-Dutra, William · M. Melo, Camila · Chaves, Luiz P. · Crozier, Cheryl · P. Saggioro, Fabiano · Tomohiro Aoki · Olivia Singh · Sheila Mansouri
▲
Breakthroughs420 · 33%
▲ 31%→34% share
▲1.1× share momentum1 median citations94% since 2021mostly methods-led
Tumor microenvironment breakthrough research surged 9→204 papers, signaling rapidly intensifying Canadian focus on TME-targeted discoveries.
rising sub-themes (early→recent)
- Tumor microenvironment9→204
- Immune system2→159
- Cancer research14→135
- Immunotherapy1→113
- Cancer immunotherapy1→65
Newly emergingCytotoxic T cell 0→30 · Transcriptome 0→19 · T cell 0→18
Landmark Pan-cancer single-cell landscape of tumor-infiltrating T cells · 1,311 cites
◆
Advancements587 · 46%
▲ 41%→46% share
▲1.1× share momentum1 median citations91% since 2021mostly empirical
Immunotherapy advancements are intensifying — Canadian papers rose 7→184, with pancreatic, colorectal, and breast cancer newly entering the segment.
rising sub-themes (early→recent)
- Tumor microenvironment11→286
- Immune system11→223
- Immunotherapy7→184
- Cancer research17→177
- Cancer immunotherapy3→68
Newly emergingBreast cancer 0→29 · Colorectal cancer 0→21 · Pancreatic cancer 0→19
Landmark Reprogramming of fatty acid metabolism in cancer · 1,574 cites
▼
Concerns153 · 12%
▼ 13%→12% share
▼0.9× share momentum3 median citations90% since 2021mostly reviews
Immune checkpoint concerns are newly emerging, with oncolytic virus safety questions also appearing fresh alongside immunotherapy concern papers rising 2→72.
rising sub-themes (early→recent)
- Immunotherapy2→72
- Tumor microenvironment4→63
- Immune system3→60
- Cancer immunotherapy1→29
- Cancer research2→24
Newly emergingImmune checkpoint 0→13 · Oncolytic virus 0→10 · Lung cancer 0→9
Landmark A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future · 930 cites
RESEARCH HOTSPOTS · Canada
Where oncology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Montreal180 · +0.52
Toronto128 · +0.49
Edmonton/Calgary66 · +0.50
Vancouver50 · +0.52
Waterloo/Hamilton47 · +0.47
Ottawa/Kingston42 · +0.52
PATENT SIGNAL · Canada
Who's filing oncology patents in Canada
Canada oncology patent filing is accelerating — 81 filings from 30 assignees (2017–2025), led by Fusion Pharmaceuticals, Lilly ELI, Zymeworks; annual filings 2→6.
81 filings30 assigneespeak 16/yr2017–2025
filing momentum (YoY 2017–2025)
top patent filers
- Fusion Pharmaceuticals35
- Lilly ELI20
- Zymeworks18
- The Royal Institution For The Ad9
- Turnstone7
- UNIV Laval5
- Grinshtein Natalie4
- Burak ERIC Steven4
Common questions
How many Oncology companies are there in Canada?
Radar tracks 183 indexable Oncology companies headquartered in Canada that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Canada?
The Oncology companies in Canada on this list have raised a combined $2.9B in disclosed equity funding across 88 funded companies.
Which is the highest-funded Oncology company in Canada?
Virogin Biotech is the highest-funded Oncology company in Canada, with $281M in disclosed equity funding.
How many Oncology companies in Canada are funded?
88 of the 183 Oncology companies in Canada on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Canada?
None of the Oncology companies in Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Canada Oncology companies?
The most active investors in Canada Oncology companies on this list include BDC, adMare BioInnovations, Lumira Ventures, Amplitude, Fonds de solidarite FTQ.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.